HK1037141A1 - Use of endothelin receptor antagonists for producing drugs for controlling obesity. - Google Patents
Use of endothelin receptor antagonists for producing drugs for controlling obesity.Info
- Publication number
- HK1037141A1 HK1037141A1 HK01107896A HK01107896A HK1037141A1 HK 1037141 A1 HK1037141 A1 HK 1037141A1 HK 01107896 A HK01107896 A HK 01107896A HK 01107896 A HK01107896 A HK 01107896A HK 1037141 A1 HK1037141 A1 HK 1037141A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptor antagonists
- endothelin receptor
- controlling obesity
- producing drugs
- obesity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19754082A DE19754082A1 (de) | 1997-12-05 | 1997-12-05 | Methode zur Bekämpfung der Fettleibigkeit |
PCT/EP1998/007501 WO1999029308A2 (de) | 1997-12-05 | 1998-11-21 | Methode zur bekämpfung der fettleibigkeit |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1037141A1 true HK1037141A1 (en) | 2002-02-01 |
Family
ID=7850913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01107896A HK1037141A1 (en) | 1997-12-05 | 2001-11-09 | Use of endothelin receptor antagonists for producing drugs for controlling obesity. |
Country Status (17)
Country | Link |
---|---|
US (1) | US6197780B1 (ru) |
EP (1) | EP1035851B1 (ru) |
JP (1) | JP2002512173A (ru) |
KR (1) | KR20010032779A (ru) |
CN (1) | CN1152685C (ru) |
AT (1) | ATE204172T1 (ru) |
AU (1) | AU751053B2 (ru) |
BR (1) | BR9815335A (ru) |
CA (1) | CA2311423C (ru) |
CZ (1) | CZ300442B6 (ru) |
DE (2) | DE19754082A1 (ru) |
ES (1) | ES2162493T3 (ru) |
HK (1) | HK1037141A1 (ru) |
HU (1) | HUP0100171A3 (ru) |
NO (2) | NO324694B1 (ru) |
RU (1) | RU2292891C2 (ru) |
WO (1) | WO1999029308A2 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
EP1130027A1 (de) * | 2000-02-29 | 2001-09-05 | Aventis Pharma Deutschland GmbH | Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben |
US20050175667A1 (en) * | 2004-02-10 | 2005-08-11 | Wenda Carlyle | Use of endothelin antagonists to prevent restenosis |
EP2190433A2 (en) | 2007-08-22 | 2010-06-02 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
PL3628320T3 (pl) | 2011-11-11 | 2022-07-25 | Gilead Apollo, Llc | Inhibitory acc i ich zastosowania |
WO2016099233A2 (ru) * | 2014-10-20 | 2016-06-23 | Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" | Фармацевтическая композиция для лечения туберкулеза |
AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
SI3380479T1 (sl) | 2015-11-25 | 2023-04-28 | Gilead Apollo, Llc | Triazolni inhibitorji ACC in uporabe le-teh |
CA3004796C (en) | 2015-11-25 | 2023-11-14 | Gilead Apollo, Llc | Pyrazole acc inhibitors and uses thereof |
CA3004798C (en) | 2015-11-25 | 2023-10-31 | Gilead Apollo, Llc | Ester acc inhibitors and uses thereof |
EP3379933B1 (en) | 2015-11-25 | 2023-02-15 | Gilead Apollo, LLC | Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine |
EP4364795A3 (en) | 2016-03-02 | 2024-08-14 | Gilead Apollo, LLC | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
US20180280394A1 (en) | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Methods of treating liver disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012499A1 (en) * | 1992-12-01 | 1994-06-09 | The Green Cross Corporation | 1,8-naphthyridin-2-one derivative and use thereof_ |
WO1997008169A1 (en) | 1995-08-24 | 1997-03-06 | Warner-Lambert Company | Furanone endothelin antagonists |
JP3116347B2 (ja) * | 1996-11-13 | 2000-12-11 | 田辺製薬株式会社 | 医薬組成物 |
-
1997
- 1997-12-05 DE DE19754082A patent/DE19754082A1/de not_active Withdrawn
-
1998
- 1998-11-21 JP JP2000523980A patent/JP2002512173A/ja active Pending
- 1998-11-21 DE DE59801230T patent/DE59801230D1/de not_active Expired - Lifetime
- 1998-11-21 US US09/530,131 patent/US6197780B1/en not_active Expired - Lifetime
- 1998-11-21 BR BR9815335-8A patent/BR9815335A/pt not_active Application Discontinuation
- 1998-11-21 KR KR1020007006075A patent/KR20010032779A/ko not_active Application Discontinuation
- 1998-11-21 EP EP98965685A patent/EP1035851B1/de not_active Expired - Lifetime
- 1998-11-21 WO PCT/EP1998/007501 patent/WO1999029308A2/de not_active Application Discontinuation
- 1998-11-21 AU AU21535/99A patent/AU751053B2/en not_active Ceased
- 1998-11-21 AT AT98965685T patent/ATE204172T1/de active
- 1998-11-21 HU HU0100171A patent/HUP0100171A3/hu unknown
- 1998-11-21 CN CNB988118327A patent/CN1152685C/zh not_active Expired - Fee Related
- 1998-11-21 CZ CZ20002006A patent/CZ300442B6/cs not_active IP Right Cessation
- 1998-11-21 CA CA002311423A patent/CA2311423C/en not_active Expired - Fee Related
- 1998-11-21 ES ES98965685T patent/ES2162493T3/es not_active Expired - Lifetime
-
2000
- 2000-05-30 NO NO20002777A patent/NO324694B1/no not_active IP Right Cessation
-
2001
- 2001-11-09 HK HK01107896A patent/HK1037141A1/xx not_active IP Right Cessation
-
2003
- 2003-12-29 RU RU2003138080/15A patent/RU2292891C2/ru not_active IP Right Cessation
-
2007
- 2007-08-30 NO NO20074419A patent/NO20074419L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2292891C2 (ru) | 2007-02-10 |
US6197780B1 (en) | 2001-03-06 |
KR20010032779A (ko) | 2001-04-25 |
WO1999029308A3 (de) | 1999-09-30 |
CZ300442B6 (cs) | 2009-05-20 |
WO1999029308A2 (de) | 1999-06-17 |
AU2153599A (en) | 1999-06-28 |
DE19754082A1 (de) | 1999-06-10 |
ATE204172T1 (de) | 2001-09-15 |
EP1035851A2 (de) | 2000-09-20 |
ES2162493T3 (es) | 2001-12-16 |
CA2311423A1 (en) | 1999-06-17 |
BR9815335A (pt) | 2000-10-17 |
CN1152685C (zh) | 2004-06-09 |
DE59801230D1 (de) | 2001-09-20 |
HUP0100171A2 (hu) | 2003-02-28 |
JP2002512173A (ja) | 2002-04-23 |
CN1301162A (zh) | 2001-06-27 |
NO20002777D0 (no) | 2000-05-30 |
HUP0100171A3 (en) | 2003-10-28 |
EP1035851B1 (de) | 2001-08-16 |
AU751053B2 (en) | 2002-08-08 |
NO20002777L (no) | 2000-06-02 |
CA2311423C (en) | 2008-01-29 |
NO20074419L (no) | 2000-06-02 |
NO324694B1 (no) | 2007-12-03 |
RU2003138080A (ru) | 2005-06-10 |
CZ20002006A3 (cs) | 2000-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1037141A1 (en) | Use of endothelin receptor antagonists for producing drugs for controlling obesity. | |
EP1958965A3 (en) | Agonist antibodies to a musk receptor, and their therapeutic uses | |
EP1231218A3 (en) | An appetite-suppressing peptide, its compositions and use | |
PT1047781E (pt) | Receptores de il-18 | |
EE04630B1 (et) | Tsentraalse kannabinoidretseptori antagonistide kasutamine ravimi valmistamisel apetentsi reguleerimiseks | |
IL129968A (en) | Use of cntf receptor activators for the manufacture of a medicament for a medicament for the treatment of obesity | |
NO20011759L (no) | Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi | |
AU4597796A (en) | Steroid receptor modulator compounds and methods | |
PL352367A1 (en) | Glucagon antagonists/inverse agonists | |
AU9386398A (en) | Cysteine rich receptors: trail | |
AR019671A1 (es) | Uso de una cantidad terapeuticamente efectiva de (+) norcisaprida o una sal farmacologicamente aceptable de la misma sustancialmente libre de su (-)estereoisomero, para la preparacion de un medicamento | |
ZA969775B (en) | Endothelin receptor antagonists. | |
EP1181555A4 (en) | CANCER TREATMENT WITH ENDOTHELINE RECEPTOR ANTAGONISTS | |
MY134167A (en) | Biphenylcarboxamides useful as lipid lowering agents | |
EP0759441A3 (en) | Methods of treating neuropeptide Y-associated conditions | |
AU2675795A (en) | Tbp2 fragments of the transferrine receptor of neisseria meningitidis | |
AU3745795A (en) | Use of CCK-B receptor antagonists for the treatment of sleepdisorders | |
NZ337087A (en) | C-terminal fragment of pancreatic lipase for hyperlipaemia, obesity, and cardiovascular disorders | |
EP1090994A3 (en) | Peptide repeat immunogens | |
AU3087599A (en) | Human appetite control by glucagon-like peptide receptor binding compounds | |
EP0754464A3 (en) | Methods of treating neuropeptide Y-associated conditions | |
WO1995022609A3 (en) | Human glutamate receptor proteins | |
ZA966552B (en) | Endothelin receptor antagonists. | |
WO1999053064A3 (en) | Methods of delivering glp-1 | |
PT759759E (pt) | Promotores para o receptor do tnf p75 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20141121 |